<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The spectacular ability of Epstein-Barr virus (EBV) to immortalize and morphologically transform human B cells in vitro to lymphoblastoid cell lines (LCLs) is central to most molecular models of <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, binding of transcription factor and oncoprotein c-Myc to the major locus control region (LCR) of the <z:mp ids='MP_0001799'>viral</z:mp> genome directs us to an alternative model for the origin of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>In this model, improved nuclear maintenance of the <z:mp ids='MP_0001799'>viral</z:mp> genome and the continuous expression of anti-apoptotic functions in B cells exhibiting class I EBV latency contribute to the generation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, without any detour through EBV nuclear antigen (EBNA) 2-driven B-cell immortalization (also called class III latency) </plain></SENT>
</text></document>